Sign inCreate account

Report workspace tools

NCT00239720TERMINATEDanonymous

Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)

Sponsor

Source record

National Institute of Allergy and Infectious Diseases (NIAID)

Phase

Source record

Phase 2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Psoriatic Arthritis

Indication / condition

AI-normalized

Arthritis, Psoriatic

Intervention

Source record

hOKT3gamma1(Ala-Ala), Placebo

Source & freshness

Source record

NCT ID

NCT00239720

Original source

ClinicalTrials.gov

Source last updated

Apr 27, 2017

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00239720

Title

Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Status

TERMINATED

Phase

Phase 2

Condition raw

Arthritis, Psoriatic

Condition normalized

Arthritis, Psoriatic

Modality raw

Arthritis, Psoriatic

Modality normalized

monoclonal antibody

Target raw

Psoriatic Arthritis

Target normalized

Psoriatic Arthritis

Interventions

hOKT3gamma1(Ala-Ala), Placebo

Public preview

Source record

The clinical trial evaluated the safety and efficacy of hOKT3γ1 (Ala-Ala), a monoclonal antibody targeting CD3 on T cells, in patients with psoriatic arthritis unresponsive to standard therapies. The study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and aimed to provide a new treatment option for patients with severe disease.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00239720

Status

TERMINATED

Phase

Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Executive brief

Investment-Ready Snapshot

The clinical trial evaluated the safety and efficacy of hOKT3γ1 (Ala-Ala), a monoclonal antibody targeting CD3 on T cells, in patients with psoriatic arthritis unresponsive to standard therapies. The study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and aimed to provide a new treatment option for patients with severe disease.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 27, 2017
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00239720

Indication

Arthritis, Psoriatic

Modality

monoclonal antibody

Target

Psoriatic Arthritis

Intervention

hOKT3gamma1(Ala-Ala), Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.